Antonino Neri

Q: What Schools Are Affiliated With Antonino Neri

Antonino Neri is affiliated with the following schools: University of California, Berkeley, University of Milan, Stanford University, University of Siena, University of Padua, University of Genoa, Columbia University

Antonino Neri's AcademicInfluence.com Rankings

Antonino Neri

Computer Science

#8439

World Rank

#8872

Historical Rank

Computational Linguistics

#1881

World Rank

#1901

Historical Rank

Machine Learning

#3458

World Rank

#3501

Historical Rank

Artificial Intelligence

#3758

World Rank

#3813

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Antonino Neri's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Antonino Neri Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Antonino Neri's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells 〉 (2001) (1009)
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. (1991) (939)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review (2009) (813)
BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. (1998) (528)
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50 (1991) (316)
EFA6, a sec7 domain‐containing exchange factor for ARF6, coordinates membrane recycling and actin cytoskeleton organization (1999) (292)
Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. (1988) (291)
Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. (1991) (268)
Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. (1988) (250)
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. (2009) (248)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. (2008) (243)
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. (2011) (237)
RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS (2014) (235)
Analysis of RAS oncogene mutations in human lymphoid malignancies. (1988) (233)
A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. (1997) (218)
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence (2012) (211)
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. (2015) (200)
Ras oncogene mutation in multiple myeloma (1989) (187)
IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. (2001) (185)
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. (2018) (183)
Oct‐4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker (2007) (178)
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth (2013) (175)
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. (2006) (169)
Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma [see comments] (1991) (168)
Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. (2010) (160)
Immunoglobulin and T-cell receptor beta-chain gene rearrangement analysis of Hodgkin's disease: implications for lineage determination and differential diagnosis. (1986) (158)
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity (2018) (154)
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 (2012) (148)
Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. (2005) (133)
The Histone Methyltransferase MMSET/WHSC1 Activates TWIST1 to Promote an Epithelial-Mesenchymal Transition and Invasive Properties of Prostate Cancer (2012) (132)
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma (2012) (132)
A SNP microarray and FISH‐based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect (2009) (130)
The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. (2007) (129)
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma (2005) (127)
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma (2013) (126)
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. (2003) (125)
p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy (1993) (124)
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma (2008) (124)
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells (2010) (122)
Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. (2005) (121)
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. (2012) (117)
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation (2012) (117)
Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies. (1993) (116)
Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients (2002) (114)
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations (2001) (113)
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers (2016) (113)
Differential repetitive DNA methylation in multiple myeloma molecular subgroups. (2009) (112)
Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. (1994) (112)
p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. (1993) (109)
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells (2007) (108)
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo (2015) (103)
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. (2017) (101)
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. (2012) (100)
Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma (2009) (96)
Structural and functional characterization of the promoter regions of the NFKB2 gene. (1995) (95)
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells (2013) (94)
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction (2013) (93)
A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells (2014) (92)
B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. (1991) (92)
Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. (1995) (91)
Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. (2000) (91)
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity (2014) (89)
Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. (1991) (88)
Molecular analysis of 11q13 breakpoints in multiple myeloma. (1999) (87)
Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia (2013) (86)
Molecular analysis of cutaneous B- and T-cell lymphomas. (1995) (86)
Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. (1997) (86)
Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. (2016) (86)
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma (2012) (85)
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma (2016) (83)
Plasmablastic lymphoma of the stomach. A case report. (1998) (83)
Rearranged NFKB-2 genes in lymphoid neoplasms code for constitutively active nuclear transactivators (1995) (83)
Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia (2013) (82)
Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. (1999) (82)
Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma. (1998) (81)
Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). (2000) (78)
Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. (1994) (78)
Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. (1998) (77)
Restoration of the transcription activation function to mutant p53 in human cancer cells. (1996) (76)
Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma (2016) (75)
The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma (2012) (74)
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14) (2001) (74)
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia (2014) (74)
BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. (2000) (73)
Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma (2013) (73)
Molecular and immunohistochemical analysis of the bcl‐1/cyclin D1 gene in laryngeal squamous cell carcinomas (1997) (73)
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma (2016) (72)
Molecular and transcriptional characterization of 17p loss in B‐cell chronic lymphocytic leukemia (2008) (72)
Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. (1999) (69)
Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. (1994) (68)
Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma (2007) (68)
Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease (2007) (68)
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines (2017) (68)
Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features (2013) (67)
Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion (2010) (66)
Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia (2011) (66)
Integrative high‐resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles (2009) (66)
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. (2013) (66)
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation (2015) (66)
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma (2019) (63)
The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma (2011) (63)
Genome‐wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles (2013) (62)
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia. (2020) (62)
Autoimmune cytopenias in chronic lymphocytic leukemia (2014) (62)
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer (2017) (61)
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. (2010) (61)
Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia (2009) (61)
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial (2014) (60)
Genotypic monoclonality in immunophenotypically polyclonal orbital lymphoid tumors. A model of tumor progression in the lymphoid system. The 1986 Wendell Hughes lecture. (1987) (59)
Mechanism of expression and role in transcriptional control of the proto-oncogene NFKB-2/LYT-10. (1994) (58)
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients (2016) (54)
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches (2010) (54)
Transcriptional features of multiple myeloma patients with chromosome 1q gain (2007) (54)
Characterization of a 78-residue fragment of c-Raf-1 that comprises a minimal binding domain for the interaction with Ras-GTP. (1994) (53)
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth (2016) (53)
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma (2017) (52)
Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome (2013) (52)
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns (2015) (52)
High‐throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications (2014) (52)
Long non-coding RNAs in normal and malignant hematopoiesis (2016) (52)
microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters (2014) (51)
Clinical relevance of p53 and bcl‐2 protein over‐expression in laryngeal squamous‐cell carcinoma (1998) (51)
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients (2011) (51)
Immunoglobulin and T cell receptor beta chain gene rearrangement analysis of ocular adnexal lymphoid neoplasms: clinical and biologic implications. (1987) (51)
Notch signaling drives multiple myeloma induced osteoclastogenesis (2014) (51)
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. (2016) (50)
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma (2015) (50)
Improved risk stratification in myeloma using a microRNA‐based classifier (2013) (50)
Identification of primary MAFB target genes in multiple myeloma. (2009) (49)
Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression (2011) (49)
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. (2018) (49)
Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses (2005) (49)
Prognostic significance of immunoglobulin phenotype in B cell chronic lymphocytic leukemia. (1985) (47)
p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity (2002) (46)
Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts (1997) (46)
Long Non-Coding RNAs in Multiple Myeloma (2018) (46)
Predictive value of β2-microglobulin (β2-m) levels in chronic lymphocytic leukemia since Binet A stages (2009) (46)
Analysis of p53 and ras gene mutations in endometriosis. (1994) (46)
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells’ vulnerability to DNA-damaging agents (2017) (45)
CD26 expression in mature B‐cell neoplasia: its possible role as a new prognostic marker in B‐CLL (2009) (45)
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells (2013) (45)
Human recombinant interferon alpha-2C enhances the expression of class II HLA antigens on hairy cells. (1986) (45)
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome (2016) (44)
The transactivating isoforms of p63 are overexpressed in high‐grade follicular lymphomas independent of the occurrence of p63 gene amplification (2005) (43)
Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. (1989) (43)
Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. (1999) (43)
Notch signaling deregulation in multiple myeloma: A rational molecular target (2015) (43)
MicroRNAs in the pathobiology of multiple myeloma. (2012) (43)
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. (2011) (42)
Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia (2014) (42)
Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system. (2015) (42)
Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia (2011) (41)
Analysis of p53 gene mutations in acute myeloid leukemia (1994) (41)
The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx (1998) (41)
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. (2012) (40)
Frequency of RAS and p53 mutations in acute promyelocytic leukemias. (1993) (39)
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study (2009) (39)
FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. (1998) (39)
Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. (2001) (38)
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. (2019) (38)
The oral protein-kinase C β inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines (2008) (38)
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias (2015) (38)
miR-22 suppresses DNA ligase III addiction in multiple myeloma (2018) (38)
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature (2016) (38)
The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. (1996) (38)
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients (2015) (37)
Identification of a tumor-associated mutant form of the NF-κB RelA gene with reduced DNA-binding and transactivating activities (1997) (37)
Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b (2010) (36)
A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma (2018) (36)
Compendium of FAM46C gene mutations in plasma cell dyscrasias (2016) (34)
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche (2016) (34)
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? (2020) (33)
Multiple genetic lesions in laryngeal squamous cell carcinomas (1995) (33)
Poor prognosis in non‐villous splenic marginal zone cell lymphoma is associated with p53 mutations (1997) (33)
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma (2019) (32)
Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression. (1997) (32)
Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors (2011) (32)
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways (2017) (31)
Clinical relevance of microvessel density in laryngeal squamous cell carcinomas (2001) (31)
bcl-1, bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas. (1993) (31)
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy (2017) (30)
Cyclin D1 protein expression is related to clinical progression in laryngeal squamous cell carcinomas (1997) (30)
Multiplex ligation‐dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in Chronic lymphocytic leukemia: A comparative study (2011) (30)
The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA (2015) (30)
Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma (2003) (30)
A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients (2016) (29)
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts (2017) (29)
Low-grade MALT lymphoma involving multiple mucosal sites and bone marrow (1998) (29)
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma–Enhanced Angiogenesis: A Novel Therapeutic Target?1 (2018) (28)
B‐cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities (2014) (28)
Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas (2000) (28)
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias (2018) (28)
B‐cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia (2013) (28)
MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. (1997) (28)
Mechanism of Activation and Biological Role of the c‐myc Oncogene in B‐cell Lymphomagenesis (1987) (27)
Gene array profile identifies collagen type XV as a novel human osteoblast‐secreted matrix protein (2009) (27)
Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma (2020) (27)
Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma (2018) (26)
Chromosome 2p gain in monoclonal B‐cell lymphocytosis and in early stage chronic lymphocytic leukemia (2013) (26)
Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma (2005) (26)
Identification of a novel gene, PSD, adjacent to NFKB2/lyt-10, which contains Sec7 and pleckstrin-homology domains. (1997) (26)
Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation (2003) (26)
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo (2016) (26)
Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma. (2004) (26)
EGFR through STAT3 modulates ΔN63α expression to sustain tumor‐initiating cell proliferation in squamous cell carcinomas (2013) (26)
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias (2020) (25)
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma (2020) (25)
Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing (2013) (24)
IgV gene intraclonal diversification and clonal evolution in B‐cell chronic lymphocytic leukaemia (2006) (24)
Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. (2007) (24)
Utilizing next-generation sequencing in the management of multiple myeloma (2017) (24)
Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. (2003) (24)
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening (2015) (23)
BCL10 gene mutations rarely occur in lymphoid malignancies (2000) (23)
Cyclin D3 immunoreactivity is an independent predictor of survival in laryngeal squamous cell carcinoma. (2005) (22)
EHT, a new member of the MTG8/ETO gene family, maps on 20q11 region and is deleted in acute myeloid leukemias. (1998) (22)
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine (2015) (22)
miR-29 b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp (2012) (22)
Primary plasma cell leukemia in the era of new drugs: has something changed? (2012) (22)
Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL (2010) (21)
Primary Plasma Cell Leukemia: Identity Card 2016 (2016) (21)
Molecular and transcriptional characterization of the novel 17p11.2‐p12 amplicon in multiple myeloma (2007) (21)
PI3K/AKT signaling inhibits NOTCH1 lysosome‐mediated degradation (2015) (21)
Patterns of T cell receptor gamma gene rearrangement and expression in B and T lymphoid malignancies. (1988) (21)
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia (2015) (21)
Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance (2019) (20)
Clonal evolution in therapy-related neoplasms (2017) (20)
Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias (2003) (20)
Molecular targeting of the PKC‐β inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression (2009) (19)
Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening (2017) (18)
Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? (2014) (18)
Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki‐67 labeling index (2004) (18)
LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems? (2020) (17)
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases (2018) (17)
In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma (2016) (17)
Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. (2017) (17)
The prevalence and clinical implications of c‐kit expression in plasma cell myeloma (2006) (16)
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma (2018) (16)
External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia (2013) (16)
Comparison between the CLL‐IPI and the Barcelona‐Brno prognostic model: Analysis of 1299 newly diagnosed cases (2018) (16)
Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. (2020) (16)
Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia (2013) (16)
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? (2021) (16)
Mutations in the coding region of c-myc occur independently of mutations in the regulatory regions and are predominantly associated with myc/Ig translocation. (1995) (16)
Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. (2017) (15)
Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines. (2005) (15)
Primary plasma cell leukemia 2.0: advances in biology and clinical management (2016) (15)
Evidence of clonal progression in a case of Richter syndrome (1993) (14)
Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia (2015) (14)
Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach (2020) (14)
Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence (2018) (14)
Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O‐CLL1‐GISL study (2014) (14)
Targeting Notch as a Therapeutic Approach for Human Malignancies. (2016) (14)
Long non-coding RNAs in B-cell malignancies: a comprehensive overview (2017) (14)
Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia (2008) (14)
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. (2016) (14)
Rosai-Dorfman syndrome with extranodal localizations and response to glucocorticoids: a case report. (1996) (14)
Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma (2020) (13)
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations (2011) (13)
The clinical and biological features of a series of immunophenotypic variant of B‐CLL (2010) (13)
Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFN&ggr; Dependent (2018) (13)
Global methylation patterns in primary plasma cell leukemia. (2018) (13)
CD26 Expression in Mature B-Cell Neoplasia: Its Possible Role as a New Prognostic Marker in B-CLL. (2007) (13)
p53 tumour suppressor gene and RAS oncogenes: molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia (1996) (13)
Analysis of tumor‐specific immunoglobulin gene rearrangement in peripheral blood B‐cells of multiple myeloma patients (1991) (13)
Total body computed tomography scan in the initial work‐up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O‐CLL1‐GISL study (2013) (13)
Absence of Kaposi's sarcoma--associated herpesvirus DNA sequences in multiple myeloma. (1999) (12)
Serum level of CD26 predicts time to first treatment in early B‐chronic lymphocytic leukemia (2009) (12)
Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia (2011) (12)
Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). (2013) (12)
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. (2015) (12)
Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia (2014) (12)
Immunoreactivity for cyclin D3 is frequently detectable in high‐grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation (2003) (12)
p53 Protein expression in laryngeal squamous cell carcinomas bearing wild‐type and mutated p53 gene (1996) (12)
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (2012) (11)
Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. (2011) (11)
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors (2020) (11)
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma (2021) (11)
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells (2017) (11)
Long non-coding RNAs in B-cell malignancies: a comprehensive overview. (2017) (11)
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities (2021) (11)
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? (2016) (11)
Functional and multimarker analysis of T-cell chronic lymphocytic leukaemia. (2009) (10)
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia (2019) (10)
Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression (2017) (10)
Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. (2009) (10)
Microsatellite analyses of recurrence or second primary tumor in head and neck cancer. (2005) (9)
Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia? (2009) (9)
Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1 (2003) (9)
Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study (2015) (9)
Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma (2019) (9)
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab (2018) (9)
The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged (2019) (9)
Critical Analysis of Transcriptional and Post-Transcriptional Regulatory Networks in Multiple Myeloma (2010) (9)
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. (2019) (9)
Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing (2019) (9)
The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis. (2013) (9)
Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology (2020) (9)
Intraclonal Cell Expansion and Selection Driven by B Cell Receptor in Chronic Lymphocytic Leukemia (2011) (8)
Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma (2020) (8)
miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma (2021) (8)
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab (2020) (8)
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma (2020) (8)
Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O‐CLL1‐GISL study (2016) (8)
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients (2020) (8)
IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia (2019) (8)
Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia (2016) (8)
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study (2021) (8)
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome (2020) (8)
The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods (2008) (8)
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients (2010) (7)
Molecular events underlying interleukin‐6 independence in a subclone of the CMA‐03 multiple myeloma cell line (2014) (7)
Immunohistochemical and molecular analysis of bax, bcl-2 and p53 genes in laryngeal squamous cell carcinomas. (1999) (7)
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. (2011) (6)
Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma (2021) (6)
Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma (2007) (6)
COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. (2020) (6)
Molecular analysis of cutaneous B- and T-cell lymphomas (1995) (6)
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity. (2021) (6)
Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma (2018) (6)
The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs (2019) (6)
BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL) (2011) (6)
Association Between p 53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma (2004) (6)
Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. (2011) (6)
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) (2020) (6)
What Is New in the Treatment of Smoldering Multiple Myeloma? (2021) (6)
Jagged Ligands Enhance the Pro-Angiogenic Activity of Multiple Myeloma Cells (2020) (6)
Predictive value of the CLL‐IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment (2018) (6)
Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia (2008) (6)
THE NEW TUMOR SUPPRESSOR GENE INHIBITOR OF GROWTH FAMILY MEMBER 4 (ING4) REGULATES THE PRODUCTION OF PRO-ANGIOGENIC MOLECULES BY MYELOMA CELLS AND SUPPRESSES HYPOXIA INDUCIBLE FACTOR (HIF)-1 α ACTIVITY BEING INVOLVED IN MYELOMA-INDUCED ANGIOGENESIS. (2007) (5)
B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia (2012) (5)
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity (2022) (5)
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases (2021) (5)
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity (2021) (5)
BCL-2 Gene Rearrangement and Protein Expression in Primary Cutaneous B Cell Lymphomas (1994) (5)
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome (2021) (5)
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI). (2016) (5)
Identi fi cation of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB 4 transcripts (2015) (5)
Halting the FGF/FGFR axis leads to anti-tumor activity in Waldenström's Macroglobulinemia by silencing MYD88. (2020) (5)
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma (2021) (4)
Identification of a novel IGH‐MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16·3;q32) chromosomal translocation (2004) (4)
Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line (2001) (4)
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines (2020) (4)
In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor (2013) (4)
Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases (2020) (4)
Advances in Brief Detection of t ( 4 ; 14 ) ( p 16 . 3 ; q 32 ) Chromosomal Translocation in Multiple Myeloma by Reverse Transcription-Polymerase Chain Reaction Analysis of IGH-MMSET Fusion Transcripts 1 (2000) (4)
In Vitro and In Vivo Evidences of Osteocyte Involvement In Myeloma-Induced Osteolysis (2010) (4)
Genomic profiling of enzastaurin‐treated B cell lymphoma RL cells (2011) (4)
Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective (2021) (4)
Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease (2014) (4)
ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape (2021) (4)
In Vitro Silencing of lncRNAs Using LNA GapmeRs. (2021) (4)
External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience (2009) (4)
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients (2021) (3)
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials (2022) (3)
Hypermethylation Is A Key Feature of the Transition of Multiple Myeloma to Plasma Cell Leukemia (2010) (3)
Cultivation of tissue and cell cultures of human skeletal and soft tissue tumors (1976) (3)
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. (2021) (3)
Clinical stage and immunological findings in chronic lymphocytic leukemia. (1984) (3)
Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs (2021) (3)
Analysis of BCL-10 gene mutations in ovarian cancer cell lines. (1999) (3)
Biological and molecular characterization of a rare case of cutaneous Richter syndrome (2017) (3)
Primary Soft Tissue Lymphomas: Description of Seven Cases and Review of the Literature (2017) (3)
A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14) (2002) (3)
A retained transcriptomic profile characterizes CD138+ cells in the short time progression from smoldering to active multiple myeloma. (2019) (3)
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis (2011) (3)
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials (2022) (3)
Persistent asymptomatic lymphocytosis with large granular lymphocyte predominance (NK phenotype). (1985) (3)
Immunoglobulin heavy chain variable region gene ( IGHV ) and prediction of time to first treatment ( TTFT ) in patients with chronic lymphocytic leukemia ( CLL ) : mutational load or mutational status ? Analysis of 1003 cases (2018) (3)
Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol (2021) (3)
Ras-dependent maturation of Xenopus oocytes is blocked by modified peptides of GTPase activating protein (GAP). (2009) (3)
Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. (2010) (3)
Genomic profiling of B cell lymphoma RL cell line treated with enzastaurin (2010) (3)
The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS (2010) (3)
p53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bN0M0). (1996) (3)
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients (2020) (2)
High-Throughput Sequencing For The Identification Of NOTCH1 mutations In Early Stage Chronic Lymphocytic Leukemia: Biological and Clinical Implications (2013) (2)
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma (2014) (2)
Cyclin D 3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma (2004) (2)
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials (2021) (2)
MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort (2022) (2)
New cell line derived from a human chondrosarcoma (1974) (2)
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. (2022) (2)
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells (2022) (2)
The investigation of genomic profiles in plasma cell leukemias by means of an integrative microarray approach (2011) (2)
Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings? (2021) (2)
Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine (2022) (2)
Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements (2022) (2)
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells (2013) (2)
Peripheral T-Cell Lymphomas Not Otherwise Specified: Potential Novel Molecular Entities Based on Both Tumor and Microenvironment Cellular Components (2016) (2)
Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma (2019) (2)
Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins (2022) (2)
Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial (2010) (2)
A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression (2018) (2)
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment (2021) (2)
Non‐negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms (2010) (2)
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia (2021) (2)
Molecular Modelling of NONO and SFPQ Dimerization Process and RNA Recognition Mechanism (2022) (2)
Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease (2017) (2)
Multiple myeloma-associated drug resistance : targeting the Notch pathway (2015) (1)
TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH A NEW CORTICOSTEROID, DEFLAZACORT (1991) (1)
Multiple myeloma-endothelium: 2D and 3D systems to study notch signaling (2016) (1)
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort. (2022) (1)
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. (2008) (1)
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) (2019) (1)
Characterization of Oncogene Dysregulation in Multiple Myeloma by Combined FISH and DNA Microarray Analyses. (2004) (1)
Acalabrutinib in chronic lymphocytic leukemia (2023) (1)
Gene Expression Profiling of Isolated Mesenchymal and Osteoblastic Cells Exhibits a Different Pattern of Expression in Multiple Myeloma Patients as Compared to Healthy Subjects: Potential Relationship with the Presence of Bone Lesions. (2007) (1)
Tumor Microenvironment (TME) Regulation of Programmed Death-1 (PD1) Receptor and Its Ligands PDL1 and PDL2 in Chronic Lymphocytic Leukemia (CLL) (2017) (1)
INCLUSION OF TOTAL BODY CT SCAN IN THE INITIAL WORK-UP OF CLL PATIENTS WITH EARLY-STAGE ON CLINICAL GROUNDS: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1-GISL STUDY (2009) (1)
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells (2021) (1)
Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma (2018) (1)
Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma (2002) (1)
Low dose alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia (2011) (1)
DKK-1 and sFRP-3 Expression by Myeloma Cell and Bone Marrow Plasma Levels in Multiple Myeloma and MGUS Patients: Potential Relationship with Bone Status. (2006) (1)
Analysis of p53 and ras gene mutations in hepatocellular carcinoma in Italy (1994) (1)
Repetitive DNA methylation in multiple myeloma (2008) (1)
Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent (2015) (1)
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile. (2012) (1)
Oxygen Tension in the Bone Marrow (BM) of Patients with Malignant and Indolent Monoclonal Gammopathy: Role of Hypoxia and Hypoxia-Inducible Factor (HIF)-1α in the Regulation of Gene Expression and Pro-Angiogenic Profiles of CD138+ Cells. (2009) (1)
Notch signaling dysregulation promotes multiple myeloma-associated bone disease (2015) (1)
Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma (2022) (1)
Genome-wide approach identify recurrent 8p21.2 loss in more aggressive form of primary plasma-cell leukemia (2012) (1)
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study (2015) (1)
High-resolution microarray characterization of the 13q14 deletion extent in B-cell chronic lymphocytic leukemia : correlation with copy number and expression levels of mir-15a/16 cluster (2009) (1)
PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY (2019) (1)
Improved Risk Stratification in Myeloma Using Microrna-Based Classifier (2012) (1)
FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88 (2020) (1)
Transcriptome analysis of primary plasma cell leukemia tumors from a multicenter prospective gimena study : biological and clinical implications (2012) (1)
Abstract LB-025: The role of NOTCH pathway in multiple myeloma associated drug resistance (2017) (1)
Isatuximab in multiple myeloma (2023) (1)
Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome (2015) (1)
Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study. (2022) (1)
HOXB7 Overexpression in Mesenchymal Cells Stimulates the Production of Pro-Angiogenic Molecules: Potential Role in Multiple Myeloma Associated Angiogenesis (2008) (1)
International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia (2019) (1)
Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia (2012) (1)
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 (2015) (1)
Oleil Hydroxytyrosol (HTOL) Exerts Anti-Myeloma Activity by Antagonizing Key Survival Pathways in Malignant Plasma Cells (2021) (1)
Integrative Genomic Analysis of Primary Plasma Cell Leukemia Revealed Strong Gene and MicroRNA Dosage Effect (2010) (1)
Treatment Acute Myeloid Leukemia Using Cytoreductive Chemotherapy Cytarabine (Ara-C) Followed Azacitidine (AZA) Maintenance: A Real Life Single Center Experience (2016) (1)
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). (2020) (1)
Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma (2020) (1)
A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia. (2009) (1)
7q11.23 CNV alters protein synthesis and REST-mediated neuronal intrinsic excitability (2022) (1)
The reconstruction of transcriptional regulatory networks reveals critical genes which have implications for clinical outcome of multiple myeloma (2011) (1)
The ribonuclease DIS 3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN 28 B mRNA (2015) (1)
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study (2021) (1)
The notch pathway in the interplay between myeloma cells and endothelium in the bone marrow niche (2017) (1)
Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia (2012) (1)
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma (2014) (1)
Pleiotropic anti-myeloma activity of ITF 2357 : inhibition of IL-6 receptor signalling and repression of miR-19 a and miR-19 b by (2009) (1)
Barr virus genome in AIDS-associated lymphoma Frequent c-myc oncogene activation and infrequent presence of Epstein (2005) (1)
Repetitive DNA hypomethylation in multiple myeloma (2008) (0)
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents (2023) (0)
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo. (2012) (0)
Stereotyped Subset #4 In Chronic Lymphocytic Leukemia Is Associated With Distinct Gene and Microrna Transcriptional Profile (2013) (0)
Understanding the interaction of human cancer cells with the surrounding microenvironment: the new challenge in modern oncology (2015) (0)
Prognostic significance of abdominal CT scan in CLL patients in Binet Stage a : preliminary results of a prospective, multicenter observation –CLL1 - GISL study (2010) (0)
A peculiar B-Cell subset, frequently IGVH hipermutated, is identified by a simplified immunophenotype-fish diagnostic algorithm (2005) (0)
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence (2011) (0)
The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities (2022) (0)
Targeting the Notch pathway in multiple myeloma through small molecules uncoupling Notch-Jag interaction (2015) (0)
Analysis of hiperdiploidy in Multiple Myeloma by fluorescence in situ hybridization. (2006) (0)
Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma (2022) (0)
Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia (2013) (0)
Elotuzumab in multiple myeloma (2022) (0)
Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas' (2020) (0)
Bone marrow-mediated drug resistance is promoted by Jagged-induced notch pathway in multiple myeloma (2015) (0)
Understanding the role of extracellular vesicles in the interaction of multiple myeloma with the surrounding microenvironment: the key contribution of the Notch pathway (2016) (0)
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14+ Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoc (2014) (0)
Targeting Notch to induce anakoinosis in multiple myeloma niche (2018) (0)
The Notch pathway controls multiple myeloma crosstalk with the osteoclastogenic niche (2014) (0)
Abstract 4071: Investigation of thyroid tumor microenvironment by immunohistochemical and bioinformatic analyses (2018) (0)
Abstract 1908: Search for mediators of the lethal effect of COPZ1 depletion in thyroid tumor cells (2018) (0)
Human Cancer Biology Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma (2009) (0)
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia. (2023) (0)
Author response for "Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL)" (2019) (0)
Jagged1/2 inhibition promotes multiple myeloma cell sensitivity to Bortezomib in vitro, ex-vivo and in vivo in a novel zebrafish model (2018) (0)
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. (2021) (0)
P870: DEFINING A NOVEL FUNCTION FOR THE POST-TRANSLATIONAL MODIFICATION UFMYLATION IN THE ADAPTIVE RESPONSE TO ARGININE DEPRIVATION IN MULTIPLE MYELOMA (2022) (0)
Bone Microenvironment Cells Show a Different Pattern of Gene Expression Profiling in Relationship with the Presence of Osteolytic Bone Lesions in Multiple Myeloma Patients (2008) (0)
Abstract 4575: Three-gene diagnostic classifier for ALK negative ALCL (2012) (0)
Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative. (2009) (0)
recognition of ALK-negative anaplastic large-cell lymphoma Identification of a 3-gene model as a powerful diagnostic tool for the (2012) (0)
HOXB7 Is Critically Involved in Multiple Myeloma-Induced Angiogenic Switch. (2009) (0)
Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia. (2008) (0)
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer (2017) (0)
relevance to geography and Epstein-Barr virus association Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: (2011) (0)
Sphingosine Kinase 1 as a Potential Target To Inhibit Proliferation of Myeloid Leukemia Cells. (2007) (0)
Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological features. (1982) (0)
Genome-Wide DNA Copy Number Analysis by SNP Arrays of B-Cell Chronic Lymphocytic Leukemia: Correlation with Known Biological and Molecular Prognostic Markers. (2008) (0)
the NFKB2/lyt-10 gene in lymphoid malignancies Heterogeneous chromosomal aberrations generate 3' truncations of (2011) (0)
Notch signaling and multiple myeloma: challenging endogenous and bone marrow-mediated drug resistance (2015) (0)
AKT regulation of oncogenic Notch pathway in T-cell acute lymphoblastic leukemia (2015) (0)
The improvement of flow cytometry techniques for the diagnosis of chronic lymphocytic 50 leukemia (2013) (0)
Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach (2020) (0)
Mesenchymal and Osteoblastic Cells Isolated from Multiple Myeloma Patients Reveal a Different Behavior, Phenotype and Gene Expression Profiling in Relationship with the Presence of Osteolytic Bone Lesions. (2006) (0)
Significant global hypomethylationmof DNA repetitive sequences in cell chronic lymphocitic patients with 17P deletion (2010) (0)
Notch pathway and Inteleukin-6 cooperate to support multiple myeloma cell proliferation (2015) (0)
Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study (2021) (0)
Global microrna expression profiling in multiple myeloma identifies deregulated patterns associated with distinct molecular groups (2009) (0)
Detection of the t(4;14)(p!6.3;q32) chromosomal translocation in multiple myeloma by rt-pcr analysis of 1gh-mmset fusion transcripts (2000) (0)
Genomic and functional approaches as powerful tools to stratify human T-cell lymphoproliferative disorders and to identify relevant tumorigenic culprits (2008) (0)
1.2 Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of CLL (2011) (0)
PB1761 CLINICAL IMPACT OF NPM1 MUTATION SUBTYPES IN A MONOCENTRIC COHORT OF ACUTE MYELOID LEUKEMIA (2019) (0)
A novel therapeutic approach targeted notch in multiple myeloma based on small molecules uncoupling receptor-ligand interaction (2016) (0)
The Activation of Wnt5a-Mediated Non Canonical Wnt Signaling in Human Bone Marrow Osteoprogenitor Cells Increases Osteoblastogenesis and Counterbalances the Inhibitory Effect of Myeloma Cells on Ror2/FZD5 Expression, (2011) (0)
A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma (2018) (0)
Integrative Genomic Approach Identifies Deregulated MicroRNAs in Human Myeloma Cell Lines. (2008) (0)
PS1345 CIRCULATING TUMOR DNA AS A LIQUID BIOPSY IN SMOLDERING MULTIPLE MYELOMA TO IDENTIFY BIOMARKERS OF PROGRESSION (2019) (0)
The Cytofluorimetric/FISH Diagnostic Approach Define a B-Cell Variant-CLL with Peculiar Clinico-Biological Features. (2007) (0)
Gene expression analysis of cord blood stem cells (2004) (0)
3.20 Stereotyped B-Cell Receptor is Associated with Immune Thrombocytopenia in CLL (2011) (0)
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study (2022) (0)
A new strategy of selective Notch receptor targeting in multiple myeloma based on small molecules (2018) (0)
Lymphocyte subsets in idiopathic thrombocytopenic purpura: Relationship with disease activity and therapy (1984) (0)
Prognostic Significance of Telomere Length in Chronic Lymphocytic Leukemia Patients in Early Stage Disease (2011) (0)
Gene expression signature of the apoptotic patway in indolent CLL by low-density array technology (2007) (0)
Biology of Human Tumors microRNAome Expression in Chronic Lymphocytic Leukemia : Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters (2014) (0)
IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES (2019) (0)
Notch signaling promotes drug resistance in multiple myeloma through the regulation of the CXCR4/SDF1α axis (2018) (0)
The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease (2013) (0)
LYMPHOID NEOPLASIA Identi ﬁ cation of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts (2015) (0)
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma (2021) (0)
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance (2012) (0)
Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukemia (2014) (0)
MGUS and Chip: Two Faces, but Not of the Same Medal (2021) (0)
Selective G-Protein Estrogen Receptor (GPER) Activation Triggers Anti-Multiple Myeloma Activity and Synergizes with MiR-29b-Inducing Drugs (2014) (0)
A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients (2015) (0)
Impact of COVID-19 pandemic on outpatient visit volume in cancer patients: Results of COMETA multicenter retrospective observational study (2023) (0)
Identification of specific transcriptional patterns associated with hyperdiploidy in multiple myeloma (2006) (0)
Abstract 2161: Network-based inference of ALK oncogenic signaling in T-cell lymphoproliferative disorders (2010) (0)
Arginine Deprivation Sustains Plasma Cell Fitness Via GCN2: A Novel Immuno-Metabolic Check-Point (2017) (0)
Abstract LB-269: IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies (2018) (0)
MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL) (2013) (0)
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia (2022) (0)
B-cell Receptors Lymphocytic Leukemia Is Associated with Stereotyped Immune Thrombocytopenia in Patients with Chronic Updated (2012) (0)
Reverse Engineering and Critical Analysis of Gene Regulatory Networks in Multiple Myeloma (2009) (0)
Impact of Genetic Predisposition on Glyco-Metabolic Side Effects of TKIs in CML (2020) (0)
The Notch pathway drives the ability of the bone marrow niche to promote RNA editing in multiple myeloma (2017) (0)
Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis (2019) (0)
The candidate tumor suppressor ing4 regulate IL-8 production in human multiple myeloma cells and it is involved in their pro-angiogenic properties (2006) (0)
PS1362 TRYPTOPHAN DEPRIVATION DUE TO INCREASED IDO-1 TRIGGERS A METABOLIC ADAPTIVE RESPONSE AND DOWN-REGULATES CD38 IN MULTIPLE MYELOMA (2019) (0)
Abstract 2550: Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity (2017) (0)
Bioinformatics Pipeline to Analyze lncRNA Arrays. (2021) (0)
Microenvironment Regulation of IL23R/IL-23 Axis Drives Chronic Lymphocytic Leukemia (CLL) Progression (2015) (0)
Are the myeloma bone microevironment cells tumoral or not (2009) (0)
OAB-041: Epithelial-mesenchymal-transition regulated by Junctional Adhesion Molecule-A (JAM-A) associates with aggressive extramedullary multiple myeloma disease (2021) (0)
674: ΔF508-CFTR mutation in genetically diverse collaborative cross mice expands CF disease-relevant phenotypes (2021) (0)
Integrative genomic approach of the molecular biology of multiple myeloma (2008) (0)
Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles. (2007) (0)
Clinical R elevance o f E xpression o f t he C IP/KIP C ell-Cycle Inhibitors p 21 a nd p 27 i n L aryngeal C ancer (1999) (0)
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells (2017) (0)
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort. (2023) (0)
Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY (2011) (0)
Epstein-Barr Virus Infection Precedes Clonal Expansion in Burkitt ' s and Acquired Immunodeficiency Syndrome-4 ssociated Lymphoma (2003) (0)
The Atypical Gtpase Rhou Lies Downstream IL6/STAT3 and Regulates Myeloma Plasma Cells Adhesion/Motility (2016) (0)
Long Noncoding RNA RROL Provides Chromatin Scaffold for MYC-WDR82 Interaction to Impact Lipid Metabolism and Tumor Cell Growth in Multiple Myeloma (2021) (0)
Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell Lines (2008) (0)
Jagged blockade promotes tumor cells response to Bortezomib in a zebrafish model of multiple myeloma (2019) (0)
PS1360 LONG NON-CODING RNA NEAT1 TARGETING TRIGGERS ANTI-TUMOR ACTIVITY AND RESULTS IN CHEMO-SENSITIZING EFFECT IN MULTIPLE MYELOMA CELLS (2019) (0)
Integrative high-resolution microarrays approach in B-cell chronic lymphocytic leukemia reveals the presence of molecularly distinct subgroups in patients with 13Q deletion (2009) (0)
Multiple myeloma associated angiogenesis: the notch pathway in the interplay between myeloma and endothelium (2017) (0)
Definition of a Prognostic Scoring System for Predicting Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia. (2006) (0)
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials (2022) (0)
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study. (2023) (0)
Hypoxia-inducible factor (HIF)-1 alpha as a therapeutical target in myeloma induced angiogenesis and bone destruction in vitro and in vivo (2012) (0)
Apoptosis Taqman Low-Density Array: Analysis of Programmed Cell Death Patway in CLL. (2007) (0)
Abnormal immunoglobulin serum free light chains (SFLC) are associated with cellular and molecular markers and predict therapy requirements (TFS) in patients with chronic lymphocytic leukemia (2010) (0)
The Notch pathway controls multiple myeloma induced osteoclastogenesis (2013) (0)
Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing (2019) (0)
Genome-Wide Analysis of Primary Plasma-Cell Leukemia Identifies Recurrent Imbalances Associated with Transcriptional Profile Alterations (2011) (0)
Gene expression profiling of plasma cell dyscrasias: The role of IGH translocations in the heterogeneity of multiple myeloma. (2004) (0)
Jagged-directed therapy in multiple myeloma: a new approach to interrupt the crosstalk between the tumor cell and the bone marrow microenvironment (2017) (0)
P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS (2022) (0)
Hypoxia increases multiple myeloma stem cells by modulating notch signalling (2016) (0)
The value of serum beta 2-microglobulin (beta-2M) in comparison with CD38 and ZAP-70 expression, and IGVH gene status in predicting therapy free interval in early B-cell chronic lymphocytic leukemia (B-CLL) patients (2007) (0)
Notch targeting prevents multiple myeloma associated osteoclastogenesis (2014) (0)
Microfind approach for fish detection of genetic lesions from scarce cell samples in multiple myeloma samples (2010) (0)
Effect of Dioxin (TCDD) on Gene Transcription of Human CD34+ Hematopoietic Cells. (2007) (0)
Arrangements and Rearrangements of the Human T‐cell Receptor Gamma Gene a (1987) (0)
Venetoclax in acute myeloid leukemia (2023) (0)
RATIONALE FOR MOLECULAR TARGETING THE COMMUNICATION OF MULTIPLE MYELOMA AND BONE MARROW NICHE: WHY NOTCH? (2017) (0)
PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS (2022) (0)
Molecular profiles associated with cyclins D dysregulation and IGH translocations in multiple myeloma (2005) (0)
Genome-wide analysis of DNA copy number changes in multiple myeloma using high-density SNP arrays (2007) (0)
P875: ACTIVATION OF LNCRNA NEAT1 LEADS TO SURVIVAL ADVANTAGE OF MULTIPLE MYELOMA CELLS BY SUPPORTING A REGULATORY LOOP WITH DNA REPAIR PROTEINS: RATIONAL BASES FOR NEAT1 THERAPEUTIC TARGETING IN THE DISEASE (2022) (0)
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia (2018) (0)
OAB-009: Genome-wide CRISPR interference screen identifies RNA Regulator of Lipogenesis (RROL) as a leading LncRNA dependency in Multiple Myeloma (2021) (0)
Jagged-induced notch signaling promotes endogenous and bone marrow-mediated drug resistance in multiple myeloma (2014) (0)
Understanding the contribute of the notch pathway in multiple myeloma bone marrowniche : a focus on extracellular vesicles-mediated communicatio (2017) (0)
Analysis ofAlterations ofOncogenes andTumor Suppressor GenesinChronic Lymphocytic Leukemia (1994) (0)
Bone marrow-mediated drug resistance is promoted by Jagged-induced Notch signaling in multiple myeloma (2014) (0)
P849: DEPLETION OF DIS3 IN MULTIPLE MYELOMA LEADS TO PERTURBATION IN RNA METABOLISM, CELL CYCLE PROGRESSION AND MITOTIC CHECKPOINT. (2022) (0)
Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts (2014) (0)
tumor-selective pharmacologic profile competitive with bortezomib CEP-18770: A novel, orally active proteasome inhibitor with a (2008) (0)
BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis (2012) (0)
A new therapeutic strategy in multiple myeloma based on small molecules directed to notch pathway (2018) (0)
The role of notch pathway in multiple myeloma progression toward IL-6 independence (2014) (0)
Role of extrac ellular vesicles-mediated communication in the crosstalk between myeloma cells and the bone marrow niche (2017) (0)
Analysis of bax, bcl-2 and p53 gene in laryngeal squamous cell carcinomas (1997) (0)
Storti HOXB7 MM 2011 LEUKEMIA (2013) (0)
Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines (2023) (0)
Analysis of CD44 expression in monoclonal gammopathies : correlation between gene expression level and flow cytometry findings (2008) (0)
Notch pathway promotes multiple myeloma cell IL-6 independence (2014) (0)
Biological and molecular characterization by integrative genomics approach of CMA-03/06, a newly established interleukin-6 independent variant of the CMA-03 human myeloma cell line (2009) (0)
Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study. (2010) (0)
The notch ligands Jagged1 and 2 are a potential therapeutic target in multiple myeloma- associated bone disease (2015) (0)
Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity (2007) (0)
Leukemia Is Associated with Stereotyped B-cell Receptors Immune Thrombocytopenia in Patients with Chronic Lymphocytic (2012) (0)
Identification of molecular classifiers and key signalling networks in T-cell lymphoproliferative disorders through gene expression profiling meta-analyses (2011) (0)
HIGH CD54 ADHESION MOLECULE EXPRESSION PREDICTS A SHORT PROGRESSION FREE SURVIVAL IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA Chronic Lymphocytic Leukemia (II) MOLECULAR AND TRANSCRIPTIONAL CHARACTERIZATION OF 17P LOSS IN B-CELL (2019) (0)
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort (2022) (0)
Targeting the immune microenvironment in Waldenström Macroglobulinemia via halting the CD40/CD40-ligand axis. (2023) (0)
Identification of microRNAexpression patterns and definition of a (2016) (0)
Notch signaling promotes bone marrow-induced drug resistance in multiple myeloma through the regulation of the CXCR4/CXCL12 system (2018) (0)
The expression signature of Anaplastic Large Cell Lymphomas: from cell line to primary tumors (2008) (0)
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma (2014) (0)
Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Chromosome Amplification in Multiple Myeloma. (2007) (0)
RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma (2020) (0)
Abstract B224: Multi‐tyrosine kinase targeting resulting in concomitant downregulation of proliferation/survival pathways dependent on FGF‐R3, Jak2 and BCMA in human multiple myeloma cells (2009) (0)
Myelodysplastic syndromes with ring sideroblasts. (2023) (0)
Transcriptional features of 1Q in multiple myeloma (2007) (0)
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma (2018) (0)
PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma (2019) (0)
Abnormal immunoglobulin serum free light chains (SFLC) ratio is associated with unfavorable prognostic markers and is a predictor of treatment free survival (TFS) in chronic lymphocytic leukemia (2010) (0)
MicroRNA genes associated with genomic alterations or gene expression modulation contribute to enhance genetic heterogeneity in Multiple Myeloma (2008) (0)
An increased number of individuals with monoclonal B-cell lymphocytosis (MBL) charachterize recent databases of chronic lymphocytic leukemia (CLL) rai stage 0 : comparison of Gisl O-Cell prospective study and Ginema cohort (2011) (0)
Integration of total body CT scan in the initial work-up of binet stage a CLL patients on clinical grounds : preliminary results of a prospective multicenter observational-CLL1 Gisl study (2010) (0)
Role of JAG1 and JAG2 ligands in promoting the angiogenic switch in multiple myeloma (2018) (0)
The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis (2012) (0)
A High Percentage of CD16+ Monocytes Correlates with the Extent of Bone Erosion in Chronic Lymphocytic Leukemia Patients: The Impact of Leukemic B Cells in Monocyte Differentiation and Osteoclast Maturation (2022) (0)
Network-based inference of ALK oncogenic signaling in T-cell lymphoproliferative disorders (2010) (0)
Integrative genomic analysis of trisomy 12 abnormality in B-cell chronic lymphocytic leukemia (2008) (0)
Network-based inference of tumorogenic culprits in human T-cell lymphoproliferative disorders (2008) (0)
Understanding the interaction between myeloma and the bone marrow niche: role of the Notch pathway in extracellular vesicles-mediated communication (2017) (0)
The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer (2023) (0)
Differentially Expressed Protein Patterns in Chronic Lymphocytic Leukemia (CLL) after Thymosin beta4 (Tb4) and Lenalidomide (Len) Treatment: Two-Dimensional Gel Electrophoresis (2DE) Analysis (2015) (0)
Abstract 770: Identification of MASTL as novel mitotic vulnerability of thyroid tumor cells (2018) (0)
Different Gene Expression Profiles of CD133+ Cells from Cord Blood and Mobilized Peripheral Blood. (2005) (0)
A novel Notch-targeted therapeutic approach in multiple myeloma based on small molecules disrupting Notch-Jagged interaction (2015) (0)
Unveiling the pathogenetic role of Stat3 in human lymphoma (2010) (0)
The Oral PKC-β Inhibitor Enzastaurin (LY317615) Suppress Phosphorylation and Induces Apoptosis in Multiple Myeloma Cell Lines by Inhibition of AKT Pathway. (2006) (0)
Prevalence of ras gene mutations in the context of a molecular classification of multiple myeloma (2006) (0)
Abstract 181: Biological and clinical relevance of quantitative global methylation in repetitive DNA sequences in B-cell chronic lymphocytic leukemia (2010) (0)
Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation (2007) (0)
Patterns of global DNA methylation identify early stage (Binet A) CLL patients with higher risk of disease progression (2012) (0)
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma. (2023) (0)
Jagged1/2 inhibition promotes tumor cells response to Bortezomib in a zebrafish model of multiple myeloma (2018) (0)
Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group (2010) (0)
Abstract 1229: Prognostic significance of telomere length in B-chronic lymphocytic leukemia patients in early stage disease (2011) (0)
Incidence of Cytogenetic Abnormalities in Newly Diagnosed Binet Stage A B-CLL and Relationship with Prognostic Biomarkers: Preliminary Results On 305 Patients Included in the Prospective O-CLL1 GISL Study. (2009) (0)
Refractory anemia with excess of blasts: a flow cytometry study of intracellular DNA. (1986) (0)
The effect of hypoxia on notch pathway in multiple myeloma niche (2016) (0)
[Analysis of the enzyme terminal deoxyribonucleotidyl transferase in lymphoma and leukemia cells]. (1984) (0)
Letters to the editor Analysis of BCL-10 gene mutations Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse (2005) (0)
Integrative genomics based on microarrays analyses reveals a correlation between allelic imbalances and gene expression patterns in multiple myeloma (2008) (0)
Identification and characterization of a novel Sec7 domain containing exchange factor specific for ARF6 (1998) (0)
Integration of Transcriptional and Mutational Data improves the Stratification of 1 Peripheral T-Cell Lymphoma 2 (2019) (0)
Iron chelation therapy (2023) (0)
Identification of genomic and proteomic signatures in lymphomas by inducible shRNA (2005) (0)
AKT promotes the oncogenic Notch signaling in T-cell acute lymphoblastic leukemia (2014) (0)
Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines (2015) (0)
Functional analysis of deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14) (2000) (0)
Immune Thrombocytopenia Associated to Low-Dose Alemtuzumab Therapy in Chronic Lymphocytic Leukemia: A Single Retrospective Center Experience (2012) (0)
Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Antonino Neri?

Antonino Neri is affiliated with the following schools:

Antonino Neri's Academic­Influence.com Rankings

Antonino Neri's Degrees

Similar Degrees You Can Earn

Why Is Antonino Neri Influential?

Antonino Neri's Published Works

Published Works

What Schools Are Affiliated With Antonino Neri?

Antonino Neri's AcademicInfluence.com Rankings